MaxCyte (NASDAQ:MXCT) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered shares of MaxCyte (NASDAQ:MXCT - Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Several other research analysts have also commented on the company. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on MaxCyte and gave the stock a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Trading Down 5.0%

MaxCyte stock traded down $0.12 during mid-day trading on Friday, hitting $2.26. The company's stock had a trading volume of 708,577 shares, compared to its average volume of 601,241. The firm has a market capitalization of $240.28 million, a PE ratio of -6.65 and a beta of 1.38. MaxCyte has a 1 year low of $2.10 and a 1 year high of $5.26. The stock's fifty day moving average is $2.53 and its two-hundred day moving average is $3.48.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million. On average, equities analysts expect that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Several hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of MaxCyte by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock valued at $93,000 after acquiring an additional 2,154 shares in the last quarter. Rhumbline Advisers raised its stake in shares of MaxCyte by 1.6% in the fourth quarter. Rhumbline Advisers now owns 153,655 shares of the company's stock valued at $639,000 after acquiring an additional 2,402 shares in the last quarter. Valmark Advisers Inc. raised its stake in shares of MaxCyte by 2.2% in the fourth quarter. Valmark Advisers Inc. now owns 115,654 shares of the company's stock valued at $481,000 after acquiring an additional 2,478 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MaxCyte by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company's stock valued at $249,000 after acquiring an additional 2,584 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of MaxCyte by 8.5% in the fourth quarter. Invesco Ltd. now owns 49,096 shares of the company's stock valued at $204,000 after acquiring an additional 3,848 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.